Last reviewed · How we verify
Nebivolol+Diltiazem
Nebivolol+Diltiazem is a Beta-blocker and calcium channel blocker combination Small molecule drug developed by Korea University Anam Hospital. It is currently FDA-approved for Hypertension, Angina pectoris, Atrial fibrillation.
Nebivolol and diltiazem work together as a beta-blocker and calcium channel blocker to reduce heart rate, blood pressure, and cardiac workload.
Nebivolol and diltiazem work together as a beta-blocker and calcium channel blocker to reduce heart rate, blood pressure, and cardiac workload. Used for Hypertension, Angina pectoris, Atrial fibrillation.
At a glance
| Generic name | Nebivolol+Diltiazem |
|---|---|
| Sponsor | Korea University Anam Hospital |
| Drug class | Beta-blocker and calcium channel blocker combination |
| Target | Beta-1 adrenergic receptor; L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nebivolol is a selective beta-1 adrenergic receptor antagonist with vasodilatory properties that reduces heart rate and contractility. Diltiazem is a non-dihydropyridine calcium channel blocker that slows atrioventricular node conduction and causes vasodilation. The combination provides additive cardiovascular effects for blood pressure control and heart rate reduction.
Approved indications
- Hypertension
- Angina pectoris
- Atrial fibrillation
Common side effects
- Bradycardia
- Dizziness
- Fatigue
- Constipation
- Headache
- Hypotension
Key clinical trials
- Rate Control in Patients With Atrial Fibrillation (NA)
- Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging (PHASE2)
- Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm (PHASE4)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebivolol+Diltiazem CI brief — competitive landscape report
- Nebivolol+Diltiazem updates RSS · CI watch RSS
- Korea University Anam Hospital portfolio CI
Frequently asked questions about Nebivolol+Diltiazem
What is Nebivolol+Diltiazem?
How does Nebivolol+Diltiazem work?
What is Nebivolol+Diltiazem used for?
Who makes Nebivolol+Diltiazem?
What drug class is Nebivolol+Diltiazem in?
What development phase is Nebivolol+Diltiazem in?
What are the side effects of Nebivolol+Diltiazem?
What does Nebivolol+Diltiazem target?
Related
- Drug class: All Beta-blocker and calcium channel blocker combination drugs
- Target: All drugs targeting Beta-1 adrenergic receptor; L-type calcium channel
- Manufacturer: Korea University Anam Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Angina pectoris
- Indication: Drugs for Atrial fibrillation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing